Reverie’s differentiated pipeline is composed of wholly-owned drug candidates as well as candidates developed in collaboration with partner organizations, including Roche and Genentech. The assets in Reverie’s pipeline are designed to address critical limitations of current therapies, for example a lack of CNS-penetrance, or novel targets with the potential to address a serious unmet need. Reverie’s kinase-focused computational platform was critical to the discovery of every one of its drug candidates.
